Close Menu

NEW YORK ─ GenMark Diagnostics said Wednesday that it has priced an approximately $70 million public offering of its common stock. Separately, Chembio Diagnostics said it has priced a $27.5 million offering of its common stock.

Carlsbad, California-based GenMark said it expects to sell 7,253,886 shares at $9.65 per share. It has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,088,082 shares at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.